<DOC>
	<DOCNO>NCT00003801</DOCNO>
	<brief_summary>RATIONALE : Cancer treatment may risk affect health outcomes later . It yet know health outcome may relate previous treatment rhabdomyosarcoma . PURPOSE : Study determine health outcome patient survive 5 year receive treatment rhabdomyosarcoma Intergroup Rhabdomyosarcoma Study Group protocols .</brief_summary>
	<brief_title>Health-Related Outcomes Patients Who Were Previously Treated Rhabdomyosarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine frequency self report health relate outcome patient rhabdomyosarcoma survive 5 year diagnosis treatment Intergroup Rhabdomyosarcoma Study Group ( IRSG ) protocols I , II , III , IV pilot . II . Determine mortality patient compare mortality general population , especially third fourth decade life . III . Determine treatment specific risk develop second malignancy follow treatment rhabdomyosarcoma potential genetic influence ( family history cancer ) . IV . Determine association decrease fertility/offspring dose , schedule , total dose alkylating agent ( especially cyclophosphamide ) receive treatment select genitourinary paratesticular primary . V. Determine effect dose location therapeutic radiation primary head neck cancer achieve final height . VI . Determine association therapy doxorubicin ( dose age receive ) cardiac vascular event . OUTLINE : Patients ( parent survive family member ) complete baseline questionnaire plus questionnaire ( offspring , family history , topic specific ) . Medical data also collect past record . PROJECTED ACCRUAL : Approximately 1600 patient accrue study .</detailed_description>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Prior registration Intergroup Rhabdomyosarcoma Study Group Study IRSI , IRSII , IRSIII , IRSIV pilot , IRSV , IRSV pilot , one protocol IRSV ( D9501 , D9502 , D9602 ) AND Survived 5 year diagnosis ( may decease ) PATIENT CHARACTERISTICS : Age : 5 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2000</verification_date>
	<keyword>long-term effect secondary cancer therapy child</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
</DOC>